STAT+: Cambridge announced as ‘investor catalyst’ hub for ARPA-H
Cambridge has been chosen as one of three national hubs for a new federal health…
Category: biotechnology
Will a government shutdown stall Medicare drug price negotiations?
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
STAT+: Intercept, once a biotech trailblazer, sells itself for less than $1 billion
Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the…
.jpg)
STAT+: Early data are promising for autoimmune disease drug from Roivant Sciences’s Immunovant
Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’s…
STAT+: Ionis inches toward first solo drug launch with late-stage trial success for rare genetic disease therapy
Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on…
STAT+: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds
The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an…
STAT+: What ever happened to biotech’s big comeback?
This was supposed to be the year of the biotech comeback, when promising new medicines…
STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial
LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain…
A thorny ALS debate at the FDA, and the promise of artificial wombs
Can the FDA be too flexible? How do you test a mechanical womb? And who…
STAT+: Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.
Thermo Fisher Scientific’s giant plant to manufacture gene therapies for drug companies is barely a year old,…
STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval
Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly…
STAT+: What to know about the polarizing ALS drug headed for FDA scrutiny next week
Years of polarizing scientific discourse and bruising online debate will come to a head next…
STAT+: Approval setback for EpiPen alternative puts spotlight on common anti-competition tactic
Americans who suffer severe allergic reactions won’t have alternatives to autoinjectors like the Epipen for…
STAT+: Hearing on Medicare drug price negotiation gets unusually heated
WASHINGTON — Republicans and Democrats fought it out over Medicare drug price negotiation Wednesday at…
STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro
As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding…
STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind
Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved…
STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism
WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of…
STAT+: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Demand for new lab space has plummeted by more than half since the end of…
STAT+: Chamber of Commerce, government clash at first court hearing on Medicare drug prices
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday…
Listen: Covid’s latest surge, Alnylam at the FDA, & the end of an era
What does Covid-19 have in store for the winter? When are good data not good…
STAT+: Machine learning biotech raises $273 million in rare successful late-stage round
Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million…
.jpg)
STAT+: FDA panel endorses Alnylam’s heart drug — after picking apart its supporting data
A group of advisers to the Food and Drug Administration voted in favor of Alnylam…
STAT+: Nick Leschly departs Bluebird Bio spinout amid restructuring, layoffs
Some two years after splitting biotech company Bluebird Bio into two entities in a bid…
STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to…
STAT+: Here are the dozens of weight loss drugs in development to catch a booming market
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit…
STAT+: Acelyrin, a rare IPO success, stumbles in its first big test
The biotech company Acelyrin, which raised more than $500 million in an IPO this year,…
Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter
Are there still too many biotech companies? How do you know when you’re in a…
Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’
Pharma giants Novo Nordisk and Eli Lilly might’ve led the way into a new era…
STAT+: Cancer care appears brighter as off-the-shelf CAR-T advances
If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future…
STAT+: Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year
Seven months after Nimbus Therapeutics sold an experimental autoimmune disease medicine to Takeda Pharmaceuticals for up to…
STAT+: Illumina names Agilent executive as new CEO
Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry,…
Opinion: Looking for a climate job? Consider biotech
More and more people, especially early career workers, want jobs fighting climate change. But when…
STAT+: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods
Seng Cheng has been working in gene therapy for nearly as long as gene therapy…
STAT+: Drug firms test medicines to halt Alzheimer’s before symptoms appear
Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations,…
STAT+: Workforce, capacity constraints slow ramp-up of new Alzheimer’s drug Leqembi
The first Alzheimer’s therapy to clearly slow cognitive decline, approved in the United States last…
STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow
On Target is a recurring feature from STAT that dives deep into the most promising…
A broad genetic test saved one newborn’s life. Research suggests it could help millions of others
CINCINNATI — Brynn Schulte nearly died twice when she was a baby, at one point…
STAT+: AstraZeneca sues to immediately stop Medicare drug price negotiation program
WASHINGTON — AstraZeneca is the sixth drug maker to pile on a legal challenge to…
Listen: Vivek’s star turn, leaky drug data, & biotech as family business
Does biotech prepare you for the presidency? Who really wants to gut the FDA? And…
STAT+: Drug makers already bet big on mRNA for cancer. Why is Biden going in, too?
WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its…
Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech
The youngest candidate on Wednesday night’s debate stage didn’t make any friends among his fellow…
STAT+: An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies
The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target…
STAT+: Apellis safety probe of eye disease drug identifies injection needle as possible cause of severe side effect
Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of…
STAT+: Former Pear Therapeutics executives start new VC firm, with biotech veteran Bob Langer as adviser
Executives from the shuttered digital health company Pear Therapeutics are launching a new VC firm,…
Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch
What difference does a day make? Who gets to have gene therapy? And are biotech…
STAT+: Health care CEOs hauled in $4 billion last year as inflation pinched workers, analysis shows
The health care industry didn’t just provide a safe haven for jittery stock investors in…
STAT+: With an age cutoff for a new gene therapy, families and doctors scramble to treat kids before their 6th birthday
In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had…
STAT+: What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment
Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that…
STAT+: Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials
Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results…
STAT+: Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach
Fresh off of the news that its drug Wegovy may not just help people lose…